OCGN Berita Forex
Ocugen Receives Health Canada Approval To Initiate Phase 3 LiMeliGhT Trial For OCU400
Biotechnology company Ocugen, Inc. (OCGN) announced Monday that Health Canada provided a "No Objection Letter" to initiate the OCU400 Phase 3 liMeliGhT clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).
RTTNews
|
59 hari yang lalu
